Astigmatism management in cataract surgery with the AcrySof toric intraocular lens

Purpose

To present clinical data from a single-center prospective clinical trial of the AcrySof toric intraocular lens (IOL).

Setting

Academic Hospital Maastricht, Maastricht, The Netherlands.

Methods

Fifty-three eyes (43 patients) had implantation of an AcrySof toric IOL. Three toric models were evaluated in cylinder powers of 1.50 diopters (D) (SN60T3; T3 group, n = 16), 2.25 D (SN60T4; T4 group, n = 14), and 3.00 D (SN60T5; T5 group, n = 23) at the IOL plane. The T5 group was subdivided into eyes that could be fully corrected (T5a, n = 13) and eyes that could be partially corrected (T5b, n = 10).

Results

Four months postoperatively, the mean uncorrected visual acuity (UCVA) was 0.77 ± 0.23 in the T3 group, 0.93 ± 0.23 in the T4 group, 0.82 ± 0.15 in the T5a group, and 0.47 ± 0.13 in the T5b group. More than 90% of the combined eyes in the T3, T4, and T5a groups achieved a UCVA of 20/40 or better, and almost 80% achieved a UCVA of 20/25 or better. Residual refractive astigmatism of less than 0.75 D was achieved in 74% of eyes and of less than 1.00 D in 91%. The mean IOL misalignment was 2.5 ± 2.1 degrees in the T3 group, 3.5 ± 2.3 degrees in the T4 group, and 4.1 ± 3.5 degrees in the T5 group.

Conclusion

Implantation of the AcrySof toric IOL proved to be an effective, safe, and predictable method of managing corneal astigmatism in cataract patients.